CA2168110A1 - Agonists and antagonists of human interleukin-10 - Google Patents

Agonists and antagonists of human interleukin-10

Info

Publication number
CA2168110A1
CA2168110A1 CA002168110A CA2168110A CA2168110A1 CA 2168110 A1 CA2168110 A1 CA 2168110A1 CA 002168110 A CA002168110 A CA 002168110A CA 2168110 A CA2168110 A CA 2168110A CA 2168110 A1 CA2168110 A1 CA 2168110A1
Authority
CA
Canada
Prior art keywords
amino acid
human
antagonist
residues
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168110A
Other languages
English (en)
French (fr)
Inventor
Chuan-Chu Chou
Xiao-Yan Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168110A1 publication Critical patent/CA2168110A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002168110A 1993-07-26 1994-07-22 Agonists and antagonists of human interleukin-10 Abandoned CA2168110A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9894393A 1993-07-26 1993-07-26
US08/098,943 1993-07-26

Publications (1)

Publication Number Publication Date
CA2168110A1 true CA2168110A1 (en) 1995-02-02

Family

ID=22271670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168110A Abandoned CA2168110A1 (en) 1993-07-26 1994-07-22 Agonists and antagonists of human interleukin-10

Country Status (17)

Country Link
EP (1) EP0711346A1 (no)
JP (1) JPH08507930A (no)
KR (1) KR960704041A (no)
CN (1) CN1127529A (no)
AU (1) AU681178B2 (no)
CA (1) CA2168110A1 (no)
CZ (1) CZ23396A3 (no)
FI (1) FI960353A (no)
HU (1) HUT73463A (no)
IL (1) IL110413A0 (no)
NO (1) NO960309D0 (no)
NZ (1) NZ269663A (no)
PL (1) PL312718A1 (no)
SG (1) SG43798A1 (no)
SK (2) SK150596A3 (no)
WO (1) WO1995003411A1 (no)
ZA (1) ZA945434B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283096B6 (sk) 1994-07-05 2003-02-04 Steeno Research Group A/S Imunomodulátory
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
DE19851675A1 (de) * 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1885863B1 (en) 2005-05-31 2014-11-19 The Regents of the University of Colorado, a body corporate Methods for delivering genes
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
WO2010040105A2 (en) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
AU2009333325B2 (en) 2008-12-17 2014-07-10 Merck Sharp & Dohme Corp. Mono- and di-peg IL-10 production; and uses
CN108129574A (zh) 2011-11-08 2018-06-08 Umc乌德勒支控股有限公司 包括白细胞介素10和白细胞介素4的融合蛋白
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
GB2600564B (en) 2019-04-19 2024-02-28 Synerkine Pharma B V A fusion protein comprising IL13

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01113229A (ja) * 1987-10-27 1989-05-01 Inahata Kenkyusho:Kk 多孔質ハニカム構成材
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CA2115060C (en) * 1991-08-06 2003-05-06 Rene De Waal Malefyt Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity

Also Published As

Publication number Publication date
AU681178B2 (en) 1997-08-21
SG43798A1 (en) 1997-11-14
IL110413A0 (en) 1994-10-21
HUT73463A (en) 1996-08-28
WO1995003411A1 (en) 1995-02-02
ZA945434B (en) 1995-01-23
CZ23396A3 (en) 1996-05-15
CN1127529A (zh) 1996-07-24
NO960309L (no) 1996-01-25
FI960353A0 (fi) 1996-01-26
NO960309D0 (no) 1996-01-25
SK8396A3 (en) 1997-03-05
PL312718A1 (en) 1996-05-13
AU7399694A (en) 1995-02-20
FI960353A (fi) 1996-01-26
JPH08507930A (ja) 1996-08-27
NZ269663A (en) 1997-09-22
EP0711346A1 (en) 1996-05-15
HU9503983D0 (en) 1996-03-28
SK150596A3 (en) 1997-04-09
KR960704041A (ko) 1996-08-31

Similar Documents

Publication Publication Date Title
CA2168110A1 (en) Agonists and antagonists of human interleukin-10
JP4423313B2 (ja) ナチュラルキラー刺激因子
US5596072A (en) Method of refolding human IL-13
Le et al. Biology of disease
EP0441900B1 (en) Natural killer stimulatory factor
EP0656947A1 (en) Human interleukin-13
WO1994004680A9 (en) Human interleukin-13
EP0672143B1 (en) Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
EP0200986B2 (en) Recombinant human interleukin-1
US20070104680A1 (en) Antibodies to natural killer stimulatory factor
CA2252557A1 (en) Antagonists of interleukin-15
US20070116668A1 (en) Lymphotoxin-beta, lymphotoxin-beta Complexes, pharmaceutical preparations and therapeutic uses thereof
EP0851030B9 (en) PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
WO2000009150A2 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
JP3652365B6 (ja) ナチュラルキラー刺激因子
EP0615546A1 (en) Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued